Last reviewed · How we verify
NCT06840145
Biomarkers of Neurodegeneration and Neuroplasticity in Parkinson's Disease Patients Treated by Bilateral M1-iTBS
NA trial testing repetitive transcranial magnetic stimulation in Parkinson's Disease in 24 participants. Completed in 12 April 2024.
12 February 2024
Quick facts
| Lead sponsor | Instituto de investigación e innovación biomédica de Cádiz |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 June 2022 |
| Primary completion | 12 February 2024 |
| Estimated completion | 12 April 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- repetitive transcranial magnetic stimulation
Conditions studied
- Parkinson's Disease — all drugs for Parkinson's Disease →
Sponsor
Instituto de investigación e innovación biomédica de Cádiz — full company profile →
Who can join
Adults 45 to 75, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Intermittent theta-burst stimulation (iTBS) is a promising therapeutic option for Parkinson's disease patients. A study involving 24 patients will assess its effectiveness in alleviating clinical deficits. Patients will undergo 5 sessions of iTBS over the bilateral M1 and a 3-month washout period. Motor evaluation, neurocognitive assessment, serum biomarkers of neurodegeneration and neuroplasticity, and structural and functional MRI evaluations will be conducted at follow-up visits.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Plasticity-Induced Motor Recovery of Bilateral Intermittent Theta Burst Stimulation in Parkinson's Disease: A Randomized, Double-Blind, Sham-Controlled, Crossover Trial.
Rashid-López R, Macías-García P, Cruz-Gómez ÁJ, Cano-Cano F, et al · · 2026 · PMID 41351806 · DOI 10.1007/s40120-025-00865-0
Verify or expand the search:
- PubMed search for NCT06840145
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of repetitive transcranial magnetic stimulation
Trials testing the same drug.
- NCT06746857 — iTBS-Neurosplasticity for Female Youth With Depression · NA · not yet recruiting
- NCT07026461 — Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulat · Phase 4 · recruiting
- NCT07106398 — The Effectiveness of rTMS on Improving Food Craving and Weight Control in Adults Without Serious Mental Illness · NA · recruiting
- NCT06813313 — Theta Burst Stimulation With an 8-Coil Versus H1-Coil for Resistant Depression · NA · not yet recruiting
- NCT06451809 — Prediction of the Response to a Course of Transcranial Magnetic Stimulation (rTMS) Based on Heart Rate Variability · suspended
Other recruiting trials for Parkinson's Disease
Currently open trials in the same condition.
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
- NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting
Other Instituto de investigación e innovación biomédica de Cádiz trials
Trials by the same sponsor.
- NCT05181605 — Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors · Phase 2, PHASE3 · unknown
- NCT05118256 — Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis · Phase 2 · unknown
- NCT05870306 — Triple Atria Extrastimuli vs Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation · NA · active not recruiting
- NCT04118504 — Intervention in Lifestyle and Therapeutic Adherence After Coronary Event Based on Web Application · NA · completed
- NCT04725526 — Efficiency of an mHealth Intervention on the Health Literacy Improvement and Self-management. · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06840145 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto de investigación e innovación biomédica de Cádiz
- Last refreshed: 21 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06840145.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing